Navigation Links
Monsanto Company Executives Adopt 10b5-1 Trading Plans
Date:10/17/2007

ST. LOUIS, Oct. 17 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) today announced that several of its executives, including: Hugh Grant, chairman, president and chief executive officer, and Robb Fraley, executive vice president and chief technology officer, have established stock trading plans in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Under these plans, the Monsanto executives have directed brokers in the sale of shares and exercise of stock options in order to diversify their personal financial portfolios. All executives have previously satisfied their Monsanto stock ownership requirements, including Mr. Grant at an amount equal to five times his annual base salary and Dr. Fraley at an amount equal to three times his annual base salary. Both Mr. Grant and Dr. Fraley hold stock in excess of their Monsanto stock ownership requirements.

Roughly 40 Monsanto executives have stock ownership requirements of varying levels. Monsanto established a stock ownership requirement in 2000 in connection with the company's initial public offering of stock. These guidelines have been amended since then, most recently in June 2006, to keep the dollar value requirements of stock ownership commensurate with base pay multiples.

In accordance with Rule 10b5-1, officers and directors of public companies may adopt plans for purchasing or selling securities in which the amount, price and date of the transactions are specified. These plans may only be entered into when the officer or director is not in possession of material, nonpublic information.

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information on Monsanto, see: http://www.monsanto.com.


'/>"/>
SOURCE Monsanto Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. Georgia stem cell company likely to stay put
3. Surgical products company wins Governors Business Plan Contest
4. Madison stem cell company gets $1M from state
5. Company still behind schedule on Milwaukee wireless project
6. Software company enters health space with RFID solutions on hold
7. Delaware company will keep NameProtect here
8. IPO-bound NimbleGen traveling in fast company
9. Wisconsin tries to woo another stem cell company
10. Company to operate in wireless Internet space
11. RedPrairie acquires Denver software company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Pa. , July 28, 2015 ... and Drug Administration has accepted for review the company,s ... factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia ... primary endpoints. Hemophilia A ... defective factor VIII; nearly all affected patients are male. ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: ... second quarter financial results on Thursday, July 30, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 /PRNewswire-USNewswire/ ... today announced the winners of its annual ... basic research by scientists who have been supported ... early career scientists to pursue innovative ideas in ... generate "proof" of concept for the early detection, ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Oct. 29 Elekta, a global leader ... Infinity*, the definitive new digital linear accelerator ... (VMAT), a very,fast Intensity Modulated Radiation Therapy ... at the 49th Annual Meeting of The ...
... FAJARDO, Puerto Rico and CORONA, Calif., Oct. ... Watson Pharmaceuticals, Inc. announced,today that under a ... Inc., Watson has launched Tilia(TM) Fe (norethindrone ... fumarate tablets), the generic,version of Warner Chilcott,s ...
... ... Exhibition, SAN ... in regenerative medicine, announced today that findings from,a preclinical study being ... Exhibition demonstrate the ability,of the Tengion Neo-Bladder Augment(TM) to restore bladder ...
Cached Biology Technology:Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors 2Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors 3Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 2Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 3Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 4Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... infection via the innate immune system. Defensins are proteins ... anti-HIV activity. However, the mechanism by which the defensins ... on February 17 in advance of publication in the ... Investigation, Theresa Chang and colleagues from Mount Sinai School ...
... cancers from Nigeria, Senegal and North America has found ... be diagnosed with a more virulent form of the ... the University of Chicago, working with colleagues at the ... North Carolina, found that breast cancers in African women ...
... in the deep recesses of the world’s oceans. What ... cold and extreme pressure of such an environment? , ... of California, San Diego, and their colleagues have used ... accurate portrayal of deep sea life forms and how ...
Cached Biology News:Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4Advancements In Genomics Foster Deep Sea Discoveries 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: